key: cord-1028396-i37wgazj
authors: Ashhurst, Anneliese S.; Tang, Arthur H.; Fajtová, Pavla; Yoon, Michael; Aggarwal, Anupriya; Stoye, Alexander; Larance, Mark; Beretta, Laura; Drelich, Aleksandra; Skinner, Danielle; Li, Linfeng; Meek, Thomas D.; McKerrow, James H.; Hook, Vivian; Tseng, Chien-Te K.; Turville, Stuart; Gerwick, William H.; O’Donoghue, Anthony J.; Payne, Richard J.
title: Potent in vitro anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin L
date: 2020-12-24
journal: bioRxiv
DOI: 10.1101/2020.12.23.424111
sha: 9c542487d9d53ad4bd300472c6180bbb7335a21b
doc_id: 1028396
cord_uid: i37wgazj

The emergence of SARS-CoV-2 in late 2019, and the subsequent COVID-19 pandemic, has led to substantial mortality, together with mass global disruption. There is an urgent need for novel antiviral drugs for therapeutic or prophylactic application. Cathepsin L is a key host cysteine protease utilized by coronaviruses for cell entry and is recognized as a promising drug target. The marine natural product, gallinamide A and several synthetic analogues, were identified as potent inhibitors of cathepsin L activity with IC50 values in the picomolar range. Lead molecules possessed selectivity over cathepsin B and other related human cathepsin proteases and did not exhibit inhibitory activity against viral proteases Mpro and PLpro. We demonstrate that gallinamide A and two lead analogues potently inhibit SARS-CoV-2 infection in vitro, with EC50 values in the nanomolar range, thus further highlighting the potential of cathepsin L as a COVID-19 antiviral drug target.

together with 32 synthetic natural product analogues, as novel inhibitors of SARS-CoV-2 126 entry. We report herein that several analogues exhibit potent inhibitory activity against CatL 127 with IC50 values in the low nanomolar to picomolar range. Several of these gallinamide A-128 inspired molecules also possess selectivity over CatB and other related cathepsin proteases 129 and do not inhibit the two viral proteases Mpro and PLpro. Finally, we demonstrate that 130 gallinamide A and two of the most active CatL-inhibiting natural product analogues potently 131 inhibit SARS-CoV-2 infection in vitro, with EC50 values in the nanomolar range, thus 132 further highlighting the potential of CatL as a COVID-19 antiviral target. 136 Gallinamide A (1) was initially screened in a SARS-CoV-2 viral infection assay in Vero 76 137 clone E6 cells (VeroE6) at the National Institute of Allergy and Infectious Disease (NIAID) 138 to gauge whether the natural product exhibited antiviral activity. Pleasingly, gallinamide A 139 was shown to decrease viral load with an IC90 of 88 nM. Following this, we further validated 140 the activity of the natural product by performing the in vitro SARS-CoV-2 infectivity assay 141 in our own laboratories using VeroE6 cells and adenocarcinomic human alveolar basal 142 epithelial cells overexpressing ACE2 (A549/ACE2). Briefly gallinamide A (1) was pre-143 incubated with 4000 VeroE6 cells in a 384-well plate for 30 minutes and then challenged 144 with 0.5 MOI SARS-CoV-2. In the absence of treatment, these conditions lead to viral 145 cytopathic effects (CPE) and cell loss that is correlated to the level of available infectious 146 virus in the initial inoculum after 72 hours. Addition of inhibitors that block viral entry 147 reduces CPE/cell loss in a dose-dependent manner. To obtain a quantitative measure of CPE, 148 the nuclei of live cells were stained, imaged and enumerated using high-content image 149 analysis software. Using this method, we could readily generate dose-dependent sigmoidal 150 inhibition curves and calculated an EC50 of 28 ± 12 nM for gallinamide A from four 151 independent experiments ( Figure S1 ). In parallel, 500 SARS-CoV-2 viral particles were 152 used to infect confluent monolayers of A549/ACE2 cells grown in 96-well plates that had 153 been incubated for 1 hr with serially diluted gallinamide A, followed by assessment of the 154 formation of CPE 96 hrs later under an inverted microscope. This showed that gallinamide 155 A at a concentration as low as 625 nM was capable of completely preventing virus-induced 156 CPE. 157 Recent studies have shown that peptidic inhibitors of CatL and other related cysteine 158 proteases also possess inhibitory activity against SARS-CoV-2 Mpro (40, 41) . In order to 159 assess the comparative activity of gallinamide A against human CatL and the viral proteases 160 Mpro and PLpro, we incubated these proteases with 10 µM of the natural product, and 161 quantified the remaining activity using fluorogenic substrates. CatL activity was completely 162 inhibited by gallinamide A at this concentration, while no inhibition of Mpro or PLpro was 163 observed ( Figure 1C) . 164 We next sought to determine the abundance of CatL in the VeroE6 and A549 cell lines. A 165 comprehensive bottom-up proteomic analysis was utilized to assess the likelihood that this protease serves as the physiological target of gallinamide A in cell-based assays ( Figure   167 S2, Data File S1). In VeroE6 cells, CatL was among the top 300 most abundant proteins 168 and in comparison, its closely related homologue cathepsin B (CatB), was 10-fold lower in 169 abundance. In contrast, A549 cells had 10-fold higher levels of CatB compared to CatL. In 170 addition to determining the abundance of CatL by proteomics, we confirmed that CatL was 171 catalytically active in VeroE6 cells by incubating lysates with the fluorogenic substrate Z-172 Phe-Arg-AMC. This activity was completely inhibited by 20 µM of Gallinamide A. CatB 173 can also cleave Z-Phe-Arg-AMC, however when a CatB-specific inhibitor, CA-074(42) was 174 added to the lysate, no inhibitory activity was observed ( Figure S3A) . These data reveal 175 that there is very little active CatB in VeroE6 lysates relative to CatL. For A549 cell extracts, 176 protease activity using Z-Phe-Arg-AMC was also inhibited by gallinamide A, however most 177 of the activity was also sensitive to CA-074 indicating that CatB is the dominant cysteine 178 cathepsin in these cells ( Figure S3B ). This activity data is supported by our proteomics 179 analysis of A549 cells where CatB was found to be more abundant than CatL ( Figure S2 ). 180 Taken together, these data suggest that the antiviral activity of gallinamide A is not due to 181 inhibition of viral (MPro and PLpro) protease targets but likely due to inhibition of host-182 derived CatL. The level of CatL differs substantially in these cell lines which supports 183 published data that some cell lines are more sensitive to cysteine protease inhibition than 184 others (23). 186 Three series of synthetic gallinamide A analogues have been developed by our laboratories 187 to date. Series 1 consist of depsipeptide compounds 2-10, with various aliphatic residues 188 incorporated at the pseudo-N-terminus, the α,β-unsaturated moiety and on the pyrrolinone 189 ring (Figure 2 ) (37). Series 2 is comprised of indolylpyrrolinone analogues 11-23 that have 190 varied functionality at the pseudo-N-terminus and the three amino acid residues within the 191 linear chain (39). Finally, series 3 analogues (24-33) possess a number of biaryl-moieties 192 appended to the pyrrolinone unit, and dimethylvaline or methylpiperidine functionalities at 193 the pseudo-N-terminus. Each of these analogues was subjected to a preliminary inhibitory 194 screen against human CatL, Mpro and PLpro (Figure 3) . For the CatL assays, compounds 195 were incubated at 416 nM; the majority of the analogues showed potent inhibition at this 196 concentration, with 21 of the compounds reducing enzymatic activity by more than 90% 197 ( Figure 3A) . Based on the lack of potency of the parent natural product 1 against Mpro and PLpro, compounds were screened at a higher concentration (10 µM) against these enzymes. 199 As with gallinamide A, none of these analogues showed appreciable inhibition of SARS- Figure S4 ). Based on the kinact/Ki constants, we determined that analogue 23 was 1.4-fold 217 more potent than the parent natural product 1, while 17, 19 and 20 were between 2.1-and 218 3.2-fold less potent than 1. 219 Given that CatB was detected in our proteomics studies using VeroE6 and A549 lysates 220 ( Figure S2) , and it has also been recently reported that a broad-spectrum activity-based 221 probe for cysteine proteases was active against both proteases in cell lysates, (23) we also (24). Importantly, targeting a host protease, as opposed to a viral protease specific to one virus or viral strain, may provide the best opportunity for broad spectrum 297 antiviral activity that is less susceptible to rapidly progressing viral mutations. CatL is 298 therefore a promising drug target for SARS-CoV-2, and also for other current or future 299 coronavirus strains, as well as other virus families including the Filoviridae, such as the 300 Ebola virus (45).

Historically, nature has been the single most successful source for the discovery of new 303 pharmaceutical lead compounds, especially in the areas of anti-infective and anticancer 304 agents (47). In this work, we demonstrate that gallinamide A, a peptide-based natural 305 product isolated from a marine cyanobacterium, and two synthetic analogues of the natural 306 product, possess potent activity against SARS-CoV-2 infectivity in monkey (VeroE6) and 307 human (A549) cells. Specifically, the parent natural product exhibited the most potent 308 inhibition of SARS-CoV-2 in VeroE6 cells, with an EC50 of 28 nM, whereas analogues 19 309 and 23 were the most potent in A549/ACE2 cells (complete inhibition of CPE at 310 nM). 310 We show that these molecules were able to inhibit CatL in both cell lines, and could 1) and analogues 17, 19 , 20 and 23 against SARS-CoV-2 infection in VeroE6 cells. The percentage inhibition of CPE was determined by high content fluorescence microscopy. Data are the mean ± SD of 3-4 independent biological replicates (see Figure S1 and Figure S9 for data).

World Health Organization, WHO Director-General's opening remarks at the media 28

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for 607 COVID-19

Papain-like protease regulates SARS-CoV-2 viral spread and 612 innate immunity

Crystal structure of SARS-CoV-2 main protease provides a basis for design of 615 improved α-ketoamide inhibitors

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Structure-based design of antiviral 624 drug candidates targeting the SARS-CoV-2 main protease

Antimalarial peptides from marine cyanobacteria: isolation and structural 628 elucidation of gallinamide A

Combinatorial strategies by marine cyanobacteria: 630 symplostatin 4, an antimitotic natural dolastatin 10/15 hybrid that synergizes with the 631 coproduced HDAC inhibitor largazole

The antimalarial natural product 634 symplostatin 4 is a nanomolar inhibitor of the food vacuole falcipains

Synthesis of Gallinamide A 638 Analogues as Potent Falcipain Inhibitors and Antimalarials

Design of gallinamide A analogs as potent 642 inhibitors of the cysteine proteases human cathepsin L and Trypanosoma cruzi cruzain

The marine cyanobacterial metabolite gallinamide A is a potent and selective inhibitor of 646 human cathepsin L

Falcipain Inhibitors Based on the 649

Natural Product Gallinamide A Are Potent in Vitro and in Vivo Antimalarials

Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for 654 developing dual inhibitors against M pro and cathepsin L

Challenges for targeting SARS-CoV-2 proteases as a 658 therapeutic strategy for COVID-19. bioRxiv

CA-074, but not its methyl ester CA-074Me, is a 660 selective inhibitor of cathepsin B within living cells

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and 663 increases infectivity. bioRxiv

TMPRSS2 666 activates the human coronavirus 229E for cathepsin-independent host cell entry and is 667 expressed in viral target cells in the respiratory epithelium

Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late 670

Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory 671

Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome 672

SARS-CoV)

A small-molecule oxocarbazate 675 inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola 676 pseudotype virus infection into human embryonic kidney 293T cells

Natural Products as Sources of New Drugs over the Nearly

Four Decades from 01/1981 to 09/2019

Cathepsin L targeting in cancer treatment

Targeting cathepsin L (CL) by specific ribozymes 684 decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis

Cathepsin L is crucial for the 688 development of early experimental diabetic nephropathy

Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes 695 and pertubation of hair follicle cycling

Cathepsin L-deficient mice 698 exhibit abnormal skin and bone development and show increased resistance to 699 osteoporosis following ovariectomy

Lysosomal, cytoskeletal, and 702 metabolic alterations in cardiomyopathy of cathepsin L knockout mice

Cathepsin L protects mice from mycoplasmal infection and is essential for airway 706 lymphangiogenesis

Update on drug development targeting parasite cysteine proteases

Multiorgan and Renal Tropism of SARS-CoV-2

CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient 717 secretory cells

Substrate profiling of cysteine proteases using a combinatorial peptide library 720 identifies functionally unique specificities

Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune 723 response and establishes long-term expression of human antihemophilic factor IX in mice

Mobilization of HIV spread by diaphanous 2 dependent filopodia in infected 727 dendritic cells

Elucidating the mechanisms by which disulfiram protects against obesity and 732 metabolic syndrome

SARS-CoV-2 in human milk is inactivated by Holder pasteurisation 735 but not cold storage

General: We thank B. Hurst (NIAID) for initial evaluation of gallinamide A in a SARS-741

CoV-2 assay. The SARS-CoV-2 Mpro expression plasmid was kindly provided to us from 742

We appreciate support from the UCSD 743

Chancellor's office through an initiative to create a campus wide small molecule resource 744 library. We acknowledge the assistance of Jason Hsu, Vivian Tat, and Rayavara Kempaiah 745 for assistance with tissue culture. We would also like to thank Dr Luke Dowman for helpful

performed cell-based assays, cytotoxicity 756 experiments and proteomics and analyzed the data. A.H.T. and A.S. synthesized 757 gallinamide A (1) and analogues 11-33 and analyzed the NMR data

performed the enzymatic assays and analyzed the data

SARS-CoV-2 Mpro. A.A. and S.T. performed the in 760 vitro SARS-CoV-2 assays on VeroE6 and MRC5 cells and analyzed the data

performed the in vitro SARS-CoV-2 assays on A549 cells and analyzed the data

The authors declare no competing interests.